Muthusamy; Natarajan

Patent Applications and Registrations

Patent applications and USPTO patent grants for Muthusamy; Natarajan.The latest application filed is for "methods of treating and preventing graft versus host disease".

Company Profile

6.11.20

Muthusamy; Natarajan - Columbus CO
Muthusamy; Natarajan - Galloway OH

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Methods Of Treating And Preventing Graft Versus Host Disease App 20210121463 - Byrd; John C. ; et al.	2021-04-29
Methods of treating and preventing graft versus host disease Grant 10,695,350 - Byrd , et al.	2020-06-30
Tec Family Kinase Inhibitor Adjuvant Therapy App 20200147084 - Buggy; Joseph J. ; et al.	2020-05-14
Methods Of Treating And Preventing Graft Versus Host Disease App 20200009148 - Byrd; John C. ; et al.	2020-01-09
Treatment Of Cancer Using Anti-cd19 Chimeric Antigen Receptor App 20190388471 - June; Carl H. ; et al.	2019-12-26
Methods of treating and preventing graft versus host disease Grant 10,463,668 - Byrd , et al. No	2019-11-05
Treatment of cancer using anti-CD19 Chimeric Antigen Receptor Grant 10,357,514 - June , et al. July 23, 2	2019-07-23
Combination Of Chimeric Antigen Receptor Therapy And Amino Pyrimidine Derivatives App 20180140602 - Angst; Daniela ; et al.	2018-05-24
Methods Of Treating And Preventing Graft Versus Host Disease App 20180078555 - Byrd; John C. ; et al.	2018-03-22
Tec Family Kinase Inhibitor Adjuvant Therapy App 20180071293 - Buggy; Joseph J. ; et al.	2018-03-15
Methods of treating and preventing graft versus host disease Grant 9,795,604 - Byrd , et al. October 24, 2	2017-10-24
TEC family kinase inhibitor adjuvant therapy Grant 9,717,731 - Buggy , et al. August 1, 2	2017-08-01
Treatment Of Cancer Using Anti-cd19 Chimeric Antigen Receptor App 20150283178 - June; Carl H. ; et al.	2015-10-08
Methods Of Treating And Preventing Graft Versus Host Disease App 20150118209 - BYRD; John C. ; et al.	2015-04-30
Tec Family Kinase Inhibitor Adjuvant Therapy App 20140371241 - BUGGY; Joseph J. ; et al.	2014-12-18
FTY720 Increases CD74 Expression and Sensitizes Cancer Cells to Anti-CD74 Antibody-Mediated Cell Death App 20140056917 - Alinari; Lapo ; et al.	2014-02-27
Therapeutic agents for the treatment of leukemia Grant 8,633,161 - Perrotti , et al. January 21, 2	2014-01-21
FTY720 increases CD74 expression and sensitizes cancer cells to anti-CD74 antibody-mediated cell death Grant 8,591,892 - Alinari , et al. November 26, 2	2013-11-26
FTY720 Increases CD74 Expression and Sensitizes Cancer Cells to Anti-CD74 Antibody-Mediated Cell Death App 20130022541 - Alinari; Lapo ; et al.	2013-01-24
Therapeutic agents for the treatment of lymphoid malignancies Grant 8,318,812 - Byrd , et al. November 27, 2	2012-11-27
FTY720-derived anticancer agents Grant 8,309,768 - Chen , et al. November 13, 2	2012-11-13
Fty720-derived Anticancer Agents App 20120136063 - Chen; Ching-Shih ; et al.	2012-05-31
Methods and Compositions for Delivering Therapeutic Agents in the Treatment of B-Cell Related Disorders App 20110280913 - Byrd; John C. ; et al.	2011-11-17
Hybridization Quantitation Method for Modified Micro-RNA and -DNA Based Oligonucleotides App 20110027798 - Chan; Kenneth K. ; et al.	2011-02-03
Therapeutic Agents For The Treatment Of Leukemia App 20100256072 - Perrotti; Danilo ; et al.	2010-10-07
Therapeutic Agents For The Treatment Of Lymphoid Malignancies App 20100022655 - Byrd; John C. ; et al.	2010-01-28

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.